anti-MART-1 F5 TCR-gene-engineered lymphocytes

TCR-engineered T cells targeting MART-1 (F5 TCR) · National Cancer Institute

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for anti-MART-1 F5 TCR-gene-engineered lymphocytes, covering 2012-12-18 to 2012-12-18. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes [Phase 2]

See pricing